Neupogen

Under copycat attack, Amgen punches back with its own biosimilars
Fierce Pharma
Tue, 10/29/19 - 10:48 pm
Amgen
biosimilars
generics
Sensipar
Neulasta
Neupogen
Pfizer gets FDA approval for drug similar to Amgen's Neupogen
Marketwatch
Sat, 07/21/18 - 01:22 pm
Pfizer
FDA
biosimilars
Amgen
Neupogen
Nivestym
What to Expect From Amgen, Inc. in 2018
Motley Fool
Sun, 01/21/18 - 10:40 am
Amgen
Enbrel
Neulasta
Aranesp
Epogen
Neupogen
Prolia
Repatha
CAR-T
The 2018 biosimilar litigation landscape: A primer
BioPharma Dive
Sun, 12/17/17 - 11:35 am
biosimilars
FDA
Neupogen
Neulasta
Remicade
Epogen
Enbreal
Humira
Avastin
Herceptin
U.S. top court grapples over making copycat biologics available sooner
Yahoo/Reuters
Wed, 04/26/17 - 09:39 pm
biosimilars
Neupogen
Amgen
Supreme Court
Amgen and the BPCIA Patent Dance – Redux
FDA Law Blog
Mon, 02/20/17 - 10:07 am
Amgen
patents
BPCIA
FDA
Sandoz
Neupogen
generics
Genentech
Avastin
Amgen Fight Over Copies of Biotech Drugs Gets High Court Review
Bloomberg
Sat, 01/14/17 - 03:35 pm
Amgen
Supreme Court
Neupogen
Novartis
Sandoz
biosimilars
Amgen Products Threatened by Court Losses
Investopedia
Mon, 09/19/16 - 03:45 pm
Amgen
Apobiologix
Neupogen
Grastofil
Neulasta
Lapelga
biosimilars
patents
Will SCOTUS take up Sandoz' pivotal biosim case? New briefs call on court to weigh in
Fierce Pharma
Thu, 03/31/16 - 09:39 pm
Supreme Court
Sandoz
Novartis
biosimilars
Amgen
Neupogen
Zarxio
Amgen Asks the Supreme Court to Reject Challenge to Ruling that Notice of Commercial Marketing is Mandatory, But Asks for Review of Patent Dance Ruling Just in Case
FDA Law Blog
Tue, 03/29/16 - 11:12 am
Amgen
patents
FDA
Zarxio
Neupogen
Sandoz Petitions High Court to Review the Federal Circuit’s Decision on the BPCIA’s 180-Day Notice of Commercial Marketing Provision
FDA Law Blog
Wed, 02/17/16 - 11:33 am
Sandoz
FDA
BPCIA
Amgen
Zarxio
Neupogen
Amgen's Innovation Counters Biosimilar Pressure
Morningstar
Mon, 10/19/15 - 10:03 am
Amgen
innovation
biosimilars
Epogen
Aranesp
Neupogen
An update on first-ever US biosim Zarxio 2 weeks after its debut
BioPharma Dive
Fri, 09/18/15 - 11:42 am
Novartis
Sandoz
Zarxio
bioimilars
Amgen
Neupogen
First 'biosimilar' drug launches in the US, years after other countries
Yahoo/AP
Thu, 09/10/15 - 06:04 pm
biosimilars
Sandoz
Zarxio
Neupogen
Amgen
Sandoz: Zarxio marketing to be similar to a branded-drug launch
Fierce Pharma Marketing
Thu, 09/3/15 - 06:46 pm
Sandoz
Zarxio
biosimilars
Novartis
drug launches
Amgen
Neupogen
Novartis launches first U.S. 'biosimilar' drug at 15 pct discount
Yahoo/Reuters
Thu, 09/3/15 - 08:45 am
Novartis
biosimilars
Amgen
Neupogen
Zarxio
Sandoz
Amgen cannot stop imminent sale of Neupogen copycat: US appeals court
Yahoo/Reuters
Wed, 09/2/15 - 12:37 pm
Amgen
Neupogen
biosimilars
Zarxio
Novartis
Sandoz
Amgen: Waiting for Clarity on Generic Biotech
Barron's
Fri, 08/21/15 - 11:05 am
Amgen
generics
biosimilars
Novartis
Sandoz
Neupogen
Zarxio
AbbVie And Amgen Threatened By Biosimilars
Bidness, ETC
Mon, 08/17/15 - 07:57 am
AbbVie
Amgen
biosimilars
JNJ
Sandoz
Novartis
Humira
Neupogen
Remicade
Nuelasta
Enbrel
epoetin-alfa
Biosimilars will cut top 10 vulnerable biologics almost in half by 2020: Morningstar
Fierce Pharma Marketing
Wed, 07/22/15 - 09:36 pm
biosimilars
AbbVie
Roche
Amgen
Rituxan
Herceptin
Avastin
Neupogen
Neulasta
Epogen
Humira
Perjeta
Gazyva

Pages